Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$614M |
| 2 |
Apple
AAPL
|
+$443M |
| 3 |
BLD
TopBuild
BLD
|
+$391M |
| 4 |
SPCX
SpaceX
SPCX
|
+$329M |
| 5 |
Penumbra
PEN
|
+$203M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.96B |
| 2 |
NVIDIA
NVDA
|
+$425M |
| 3 |
SNDK
Sandisk
SNDK
|
+$88M |
| 4 |
Southern Company
SO
|
+$80.6M |
| 5 |
PPL
PPL Corp
PPL
|
+$74.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.4% |
| 2 | Industrials | 13.64% |
| 3 | Consumer Discretionary | 9.5% |
| 4 | Healthcare | 7.9% |
| 5 | Financials | 5.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
Lexeo Therapeutics
LXEO
$400M
| $130K | ﹤0.01% |
27,880
-84,292
| -75% | -$456K |
|
|
AGNT
1452
AGNT Inc
AGNT
$764M
| $129K | ﹤0.01% |
23,842
-83,181
| -78% | -$459K |
|
1453
KVH Industries
KVHI
$140M
| $128K | ﹤0.01% |
+12,902
| New | +$123K |
|
|
NXH
1454
Neighborhood Intelligence, Inc. Common Stock
NXH
$396M
| $123K | ﹤0.01% |
21,217
-228,825
| -92% | -$1.26M |
|
|
WLTH
1455
Wealthfront Corp
WLTH
$1.38B
| $120K | ﹤0.01% |
+13,412
| New | +$140K |
|
1456
National CineMedia
NCMI
$239M
| $118K | ﹤0.01% |
+31,119
| New | +$106K |
|
1457
Equinox Gold
EQX
$15.8B
| $114K | ﹤0.01% |
+11,741
| New | +$151K |
|
|
SHMD
1458
SCHMID Group
SHMD
$322M
| $114K | ﹤0.01% |
18,227
-18,724
| -51% | -$115K |
|
|
FBRT
1459
Franklin BSP Realty Trust
FBRT
$697M
| $114K | ﹤0.01% |
+13,957
| New | +$121K |
|
1460
Liberty Media Series A
FWONA
$24.2B
| $106K | ﹤0.01% |
1,207
+1,182
| +4,728% | +$97.3K |
|
1461
Novavax
NVAX
$1.47B
| $103K | ﹤0.01% |
10,931
-46,019
| -81% | -$412K |
|
1462
Kyverna Therapeutics
KYTX
$521M
| $102K | ﹤0.01% |
11,476
-37,535
| -77% | -$333K |
|
|
ZENA
1463
ZenaTech Inc
ZENA
$180M
| $101K | ﹤0.01% |
+67,059
| New | +$120K |
|
1464
AirSculpt Technologies
AIRS
$198M
| $99.8K | ﹤0.01% |
22,173
-4,727
| -18% | -$19.2K |
|
1465
Aura Biosciences
AURA
$809M
| $94.3K | ﹤0.01% |
13,278
-4,677
| -26% | -$33.5K |
|
1466
PUT
Richtech Robotics
RR
$380M
| $93.3K | ﹤0.01% |
44,000
+6,600
| +18% | +$16K |
|
1467
GoodRx Holdings
GDRX
$1.18B
| $90K | ﹤0.01% |
+31,243
| New | +$79.4K |
|
|
IMDX
1468
Insight Molecular Diagnostics
IMDX
$142M
| $82.8K | ﹤0.01% |
+14,029
| New | +$69.2K |
|
1469
Prelude Therapeutics
PRLD
$529M
| $82.5K | ﹤0.01% |
+15,475
| New | +$67.4K |
|
1470
NRX Pharmaceuticals
NRXP
$154M
| $79K | ﹤0.01% |
+19,308
| New | +$63.8K |
|
|
BEAGR
1471
Bold Eagle Acquisition Corp Right
BEAGR
| $77K | ﹤0.01% |
265,603
| – | – |
|
|
TONX
1472
TON Strategy Co
TONX
$169M
| $74.5K | ﹤0.01% |
+29,233
| New | +$86.5K |
|
1473
Sight Sciences
SGHT
$455M
| $73K | ﹤0.01% |
+13,470
| New | +$62K |
|
|
AIV
1474
Aimco
AIV
$381M
| $64.6K | ﹤0.01% |
+21,764
| New | +$83.4K |
|
1475
AMC Entertainment Holdings
AMC
$2.28B
| $64.2K | ﹤0.01% |
+33,810
| New | +$58.2K |
|
Similar funds
Michael Gelband's Q2 2026 Portfolio in Review
As of Q2 2026, Michael Gelband held 2,230 positions worth $15.5B, up 23% from $12.6B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Michael Gelband deployed $1.45B of net new capital in Q2 2026, opening 735 new positions and adding to 384 existing holdings. Its largest new stake was SpaceX: 1,938,935 shares worth $331M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Tesla, an estimated $1.96B trimmed.
- Michael Gelband's largest Q2 2026 buy was SpaceX: 1,938,935 shares worth $331M.
- Michael Gelband added most to Amazon in Q2 2026, an estimated $614M increase.
- Michael Gelband's biggest Q2 2026 reduction was Tesla, cutting an estimated $1.96B.
- Michael Gelband fully exited Southern Company in Q2 2026, selling an estimated $80.6M.
- Michael Gelband's ten largest holdings make up 31% of its $15.5B portfolio in Q2 2026.
- Michael Gelband opened 735 new positions and closed 720 in Q2 2026.
- Michael Gelband's portfolio value rose 23% quarter-over-quarter to $15.5B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.